skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

753 Total results for product and free and sample content found


Scrip Asks… What's The Current Climate For Deal-Making? (Part 1)

By Joseph Haas 20 Oct 2017

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. 

Topic Business strategies

Pink Sheet

Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says

By Derrick Gingery 20 Oct 2017

US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.

Pink Sheet

New ICH Guide To Eliminate ‘Discordant Advice’ On Juvenile Animal Studies 19 Oct 2017 NEWS

By Vibha Sharma 20 Oct 2017

Experts at the International Council for Harmonisation have nearly completed the first draft of a guideline 

Topic Clinical trials

Rose Sheet

Rosesheet article pack

19 Oct 2017

Pink Sheet

Chronic Fatigue Syndrome Research Takes Leap Forward With NIH Funding

By Brenda Sandburg 18 Oct 2017

Research centers are collaborating on projects to find causes of disease


The Art Of Contract Negotiations

By Jessica Merrill 18 Oct 2017

Janssen Biotech's Immunology President Scott White defended the company's Remicade contracting strategy

Topic Biosimilars


Smooth AdCom Passage Expected For Novo's Semaglutide Despite Retinopathy Queries

By Lucie Ellis 18 Oct 2017

Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product

Pink Sheet

EU ‘Vaccine Hesitancy’ And Why It’s A Problem For Manufacturers And Public Health

By Ian Schofield 18 Oct 2017

“Vaccine hesitancy” – the gradual decline in rates of vaccination against preventable diseases – has led to outbreaks of illnesses

Topic Vaccines

Pink Sheet

Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing

By Michael Cipriano 18 Oct 2017

Senators and witnesses rehashed years-old arguments and found little common ground

Topic Reimbursement

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: